ESCLEROSE MESIAL TEMPORAL: PREVALÊNCIA EM UM AMBULATÓRIO DE REFERÊNCIA NO HOSPITAL UNIVERSITÁRIO PROFESSOR POLYDORO ERNANI DE SÃO THIAGO
Palabras clave:
Epilepsia. Epilepsia do Lobo Temporal. Epilepsia Resistente a Medicamentos.Resumen
A epilepsia é uma doença heterogênea com alto impacto global, principalmente dentre aquelas pessoas com pobre controle clínico. Um de seus espectros é a esclerose mesial temporal, um tipo de epilepsia do lobo temporal cuja etiologia é estrutural e se caracteriza por lesões hipocampais uni ou bilaterais. Esta é a causa mais comum de epilepsia do lobo temporal farmacorresistente. Em cerca de 2/3 dos casos, ela é relacionada a um nível insatisfatório de controle clínico mediante medidas farmacológicas. Contudo, existe uma opção terapêutica adequada para o controle de crises nesta patologia, a intervenção cirúrgica.
O presente trabalho trata-se de um estudo descritivo observacional transversal o qual visa analisar a prevalência da esclerose mesial temporal e o perfil epidemiológico dos pacientes acompanhados no ambulatório de referência do Hospital Universitário Professor Polydoro Ernani de São Thiago. Mais de 80% destes possuem epilepsia resistente a medicamentos, porém apenas 22% deles foram submetidos à cirurgia. Além disso, os pacientes apresentaram um convívio médio de 34 anos com a doença.
Diante disso, propõe-se uma discussão acerca dos motivos da baixa disponibilidade da terapia cirúrgica para esclerose mesial temporal e o impacto dessa condição em nossa realidade.
Referencias
Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-82.
Tomson T, Walczak T, Sillanpaa M, et al. Sudden Unexpected Death in Epilepsy: A Review of Incidence and Risk Factors. Epilepsia. 2005;46(11):54-61.
Perrine KR. New Quality-of-Life Inventory for Epilepsy Patients: Interim Results. Epilepsia. 1993;34(4):28-33.
Hauser WA, Kurland LT. The Epidemiology of Epilepsy in Rochester, Minnesota, 1935 Through 1967. Epilepsia. 1975;16(1):1-66.
Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77.
Asadi-Pooya AA, Stewart GR, Abrams DJ, et al. Prevalence and Incidence of Drug-Resistant Mesial Temporal Lobe Epilepsy in the United States. World Neurosurg. 2017;99(1):662-6.
Blümcke I, Thom M, Aronica E, et al. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: A Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia. 2013;54(7):1315-29.
Wieser HG. Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis. Epilepsia. 2004;45(6):695-714.
Bernasconi A, Cendes F, Theodore WH, et al. Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: A consensus report from the International League Against Epilepsy Neuroimaging Task Force. Epilepsia. 2019;60(6):1054-68.
IBGE - Instituto Brasileiro de Geografia e Estatística [página na internet]. Projeções e estimativas da população do Brasil e das Unidades da Federação [acesso em 23 mar 2020]. Disponível: https://cidades.ibge.gov.br/brasil/sc/panorama
Mathon B, Ulvin LB, Adam C, et al. Surgical treatment for mesial temporal lobe epilepsy associated with hippocampal sclerosis. Rev Neurol (Paris). 2015;171(3):315-25.
Kaiboriboon K, Malkhachroum AM, Zrik A, et al. Epilepsy surgery in the United States: Analysis of data from the National Association of Epilepsy Centers. Epilepsy Res. 2015;116(1):105-9.
Ministério da Saúde (BR). NOTA INFORMATIVA No 131. 2015;
Asranna A, Menon R, Radhakrishnan A. Referral trends for temporal lobe epilepsy surgery between 2000 and 2014 in India. Neurol Clin Pract. 2019;9(4):297-303.
Thompson AC, Ivey SL, Lahiff M, et al. Delays in time to surgery for minorities with temporal lobe epilepsy. Epilepsia. 2014;55(9):1339-46.
Steiger BK, Jokeit H. Why epilepsy challenges social life. Seizure. 2017;44(1):194-8.
Jacoby A, Snape D, Baker GA. Epilepsy and social identity: the stigma of a chronic neurological disorder. Lancet Neurol. 2005;4(3):171-8.
Benbadis SR, Heriaud L, Tatum WO, et al. Epilepsy surgery, delays and referral patterns—are all your epilepsy patients controlled?. Seizure. 2003;12(3):167-70.
Helmstaedter C, May TW, Von Lehe M, et al. Temporal lobe surgery in Germany from 1988 to 2008: diverse trends in etiological subgroups. Eur J Neurol. 2014;21(6):827-34.
Thompson R, Kerr M, Glynn M, et al. Caring for a family member with intellectual disability and
. Jacoby A, Austin JK. Social stigma for adults and children with epilepsy. Epilepsia. 2007;48(9):6-9.
Engel J. What can we do for people with drug-resistant epilepsy? The 2016 Wartenberg Lecture. Neurology. 2016;87(23):2483-9.
Kobau R, Luncheon C, Zack MM, et al. Satisfaction with life domains in people with epilepsy. Epilepsy Behav. 2012;25(4):546-51.
Zanni KP, Maia Filho HS, Matsukura TS. Impacto da epilepsia no processo de escolarização de crianças e adolescentes. Rev Bras Educ Espec. 2010;16(2):215-30.
Lewis DV, Shinnar S, Hesdorffer DC, et al. Hippocampal sclerosis after febrile status epilepticus: The FEBSTAT study. Ann Neurol. 2014;75(2):178-85.
Shinnar S. Febrile Seizures and Mesial Temporal Sclerosis. Epilepsy Curr. 2003;3(4):115-8.
Curia G, Lucchi C, Vinet J, et al. Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?. Curr Med Chem. 2014;21(1):663-8.
Silva AV, Cabral FR. Ictogênese, Epileptogênese e Mecanismo de Ação das Drogas na Profilaxia e Tratamento da Epilepsia. J Epilepsy Clin Neurophysiol. 2008;14(2):39-45.
Lyseng-Williamson KA. Levetiracetam: A Review of its Use in Epilepsy. Drugs. 2011;71(4):489-514
Runge U, Arnold S, Brandt C, et al. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study. Epilepsia. 2015;56(12):1921-30.
Perucca P, Carter J, Vahle V, et al. Adverse antiepileptic drug effects: Toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009;72(14):1223-9.
Hamed SA. Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications. Expert Opin Drug Saf. 2011;10(6):913-34.
García-Peñas JJ, Fournier-Del Castillo MC, Domínguez-Carral J. Epilepsy and cognition: the role of antiepileptic drugs. Rev Neurol. 2014;58(1):37-42.
Lau T, Miller T, Klein T, et al. Temporal lobe surgery in medically refractory epilepsy: A comparison between populations based on MRI findings. Seizure. 2014;23(1):20-4.
Solli E, Colwell NA, Say I, et al. Deciphering the surgical treatment gap for drug-resistant epilepsy (DRE): A literature review. Epilepsia. 2020;61(7):1352-64.
Radhakrishnan A, Menon R, Thomas SV, et al. “Time is Brain”- How early should surgery be done in drug- resistant TLE?. Acta Neurol Scand. 2018;138(6):531-40.
Engel J. The Timing of Surgical Intervention for Mesial Temporal Lobe Epilepsy: a plan for a randomized clinical trial. Arch Neurol. 1999;56(11):1338-41.
Caplan R, Sagun J, Siddarth P, et al. Social competence in pediatric epilepsy: insights into underlying mechanisms. Epilepsy Behav. 2005;6(2):218-28.
Wilson SJ, Bladin PF, Saling MM. The burden of normality: A framework for rehabilitation after epilepsy surgery. Epilepsia. 2007;48(9):13-6.
Palleria C, Coppola A, Citraro R, et al. Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis. Expert Opin on Pharmacother. 2015;16(15):2355-71.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2021 Arquivos Catarinenses de Medicina
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
